US › Healthcare

Faeth Therapeutics, Inc. (FTH)

US · Healthcare · Biotechnology

$25.50-6.73%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-170.2M
Profit YoY
-2380.1%
EPS
$-131.45
EPS estimate
$-0.62

EPS came in at -131.45 against a street estimate of -0.62 — a miss of 21101.6%.

Key statistics

Market cap
$702.2M
Forward P/E
0.0
P/B
1.26
Book value
$-102.43
EPS (TTM)
$-142.72
52-week high
$37.90
52-week low
$7.20
50-day MA
$22.54
200-day MA
$19.02
Beta
-0.26

Analyst view

with an average price target of $54.89.

Shareholding

Insiders
1.45%
Institutions
25.99%

Largest institutional holders

FundStake
Vivo Capital, LLC2.80%
Cormorant Asset Management, LLC1.19%
StemPoint Capital LP1.03%
Millennium Management LLC0.57%
Franklin Resources Inc0.52%
Caligan Partners LP0.49%
Trails Edge Capital Partners, LP0.48%
Marshall Wace Asset Management Ltd0.26%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Faeth Therapeutics, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.